StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > BABY STEPS

<< Previous

Bullboard Posts

Next >>

Comment by LithLoveron Jul 14, 2021 10:47am

129 Views

Post# 33542095

RE:RE:RE:BABY STEPS

Should add cash on hand only changed by $153,786 from Q4 to Q1. $6,597,187, to $6,443,401

So if Q2 stays close to Q1 numbers and we have positive EBITDA, positive warrant valuation, a closed deal, $6 million in the bank and the start of Aristotle revenues you still don't think the market will like it?

Obviously the future is in Aristotle so much will depend on how many tests so far and the communication from Tripp and Care on the path forward. But a positive Q2 will move us out of this range.

LithLover wrote: Disagree. The operating expenses in Q1 were $1.7 million. Assuming they stay close to that and revenue is similar from covid of around $2-2.5 million and the start of revenue for Aristotle and they will be profitable. Factor in that the warrants and debentures will be a favorable adjustment given the lower share porice and higher Canadian dollar and we could see the first profitable and positive quarter. Financials come out Aug 16 so even a slight delay on the Care Oncology deal and it should still close before Q2 is reported.

So we could see a positive EBITDA, a positive warrant valuation and a closed deal.

frewil11 wrote: The market will not like Q2 results one bit , it is good that the company will have brought in good revenue from Covid testing but it will be zero from aristotle wich the market will not like .